Napredna pretraga

Pregled bibliografske jedinice broj: 824815

A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment


Šagud, Marina; Nikolac Perković, Matea; Vuksan-Ćusa, Bjanka; Maravić, Anja; Švob Štrac, Dubravka; Mihaljević Peleš, Alma; Živković, Maja; Kušević, Zorana; Pivac, Nela
A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment // Psychopharmacology, 233 (2016), 17; 3259-3267 doi:10.1007/s00213-016-4364-0 (međunarodna recenzija, članak, znanstveni)


Naslov
A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment

Autori
Šagud, Marina ; Nikolac Perković, Matea ; Vuksan-Ćusa, Bjanka ; Maravić, Anja ; Švob Štrac, Dubravka ; Mihaljević Peleš, Alma ; Živković, Maja ; Kušević, Zorana ; Pivac, Nela

Izvornik
Psychopharmacology (0033-3158) 233 (2016), 17; 3259-3267

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Antidepressants ; depression ; plasma BDNF ; platelet serotonin ; vortioxetine

Sažetak
Abstract BACKGROUND: Various antidepressants occupy brain serotonin transporter (SERT), decrease platelet serotonin (5-HT) concentration, and normalize reduced plasma brain-derived neurotrophic factor (BDNF) concentrations in depressed patients. Vortioxetine is a recently introduced antidepressant with a multimodal mechanism of action. In addition to SERT inhibition, vortioxetine acts via different 5-HT receptors. To further elucidate its mechanism of action, we have investigated the effects of vortioxetine on platelet 5-HT and plasma BDNF concentrations in patients with major depression. METHODS: Platelet 5-HT and plasma BDNF concentrations were determined in 44 healthy subjects at baseline and in 44 depressed patients before and after 4 weeks of treatment with vortioxetine (5-15 mg daily). Platelet 5-HT concentration was determined using the ortho-phthalaldehyde-enhanced fluorometric method, and plasma BDNF concentration using a commercial enzyme-linked immunosorbent assay (Quantikine ELISA, R&D Systems). RESULTS: At baseline, platelet 5-HT concentrations did not differ between depressed and control subjects, but plasma BDNF values were lower (p = 0.011 ; ω = 0.80) in depressed patients than in healthy subjects. Vortioxetine treatment significantly (p < 0.0001 ; ω = 0.80) decreased platelet 5-HT concentration and significantly (p = 0.004 ; ω = 0.80) increased plasma BDNF concentration in depressed patients compared to their baseline values. Age, gender, and smoking were not significantly associated with platelet 5-HT and plasma BDNF concentrations. CONCLUSION: Despite a novel mechanism of action, vortioxetine shares some common effects with other antidepressants. This study is the first to show that, in addition to clinical improvement, 4 weeks of treatment with vortioxetine (5-15 mg daily), decreased platelet 5-HT and increased plasma BDNF concentrations in depressed patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Napomena
Rad je objavljen iz projekta Sveučilišta u Zagrebu ; „Utjecaj religioznosti na ishod liječenja depresije: klinički i biološki pokazatelji“, BM106

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati